Extranodal Marginal Zone Lymphoma–like Presentations of Angioimmunoblastic T-Cell Lymphoma

Kaffenberger, Benjamin H.; Haverkos, Brad M.; Tyler, Kelly; Wong, Henry K.; Porcu, Pierluigi; Gru, Alejandro A.

doi:10.1097/dad.0000000000000266

Cited by 19 publications

(7 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On rare occasions, diffuse large B-cell lymphomas can develop within this tumors in the skin. Clonal plasma cells can be associated with marginal zone lymphoma-like presentations of AITL 86. PCSM-TLPD is a rare indolent cutaneous lymphoproliferative disorder that typically presents as a single asymptomatic nodule of the face or upper trunk.…”

mentioning

confidence: 99%

Cutaneous reactive B‐cell lymphoid proliferations

Khalil

Donthi²,

Gru

2022

J Cutan Pathol

View full text Add to dashboard Cite

Cutaneous lymphoid hyperplasia (CLH), also known as cutaneous pseudolymphoma, is a spectrum of benign conditions characterized by reactive B‐ and T‐cell cutaneous lymphocytic infiltrates. B‐cell lymphoid proliferations are a heterogenous group of non‐neoplastic cutaneous diseases that must be histopathologically distinguished from cutaneous B‐cell lymphomas. These proliferations can be observed as reactive phenomena to infections, medications, allergens, neoplasms, and more. Furthermore, there are many inflammatory conditions that present with reactive B‐cell infiltrates, including actinic prurigo, Zoon balanitis, Rosai‐Dorfman disease, and cutaneous plasmacytosis. This review summarizes multiple cutaneous B‐cell lymphoid proliferations within the major categories of reactive and disease‐associated CLH. Further we discuss major discriminating features of atypical CLH and malignancy. Understanding the specific patterns of B‐cell CLH is essential for the proper diagnosis and treatment of patients presenting with such lesions.

show abstract

mentioning

confidence: 99%

Cutaneous reactive B‐cell lymphoid proliferations

Khalil

Donthi²,

Gru

2022

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…definition, patients may develop accompanying B-cell lymphoproliferative disorders or clonal plasma cell proliferations as reported previously. 7,8 Importantly, recent studies have shown that AITL has a gene expression profile similar to that of follicular helper T (T FH ) cells, 2,9,10 a subset of T helper cells in the germinal center that promotes B-cell maturation and differentiation into plasma cells in cooperation with FDCs. Accordingly, in addition to expressing pan-T-cell antigens such as CD3 and CD5, the neoplastic cells of AITL usually express T FH markers such as CD10, BCL6, and/or PD-1.…”

mentioning

confidence: 99%

Cutaneous lesions of angioimmunoblastic T‐cell lymphoma: Clinical, pathological, and immunophenotypic features

et al. 2019

View full text Add to dashboard Cite

Background Angioimmunoblastic T‐cell lymphoma (AITL) is a systemic peripheral T‐cell lymphoma with a follicular helper T‐cell (TFH) immunophenotype that frequently involves the skin. However, the histopathology of cutaneous involvement by AITL has not been fully established. Methods We reviewed the clinicopathological features of 19 patients seen at our institution with AITL involving the skin. Pan‐T‐cell and TFH marker expression was evaluated by immunohistochemistry. Epstein‐Barr virus (EBV) was detected using in situ hybridization (ISH) for Epstein‐Barr virus‐encoded small RNA (EBER). T‐cell receptor (TCR) gene rearrangement was evaluated by PCR. Results AITL affected both trunk and extremities in 15/19 cases (79%). Perivascular infiltration by small and/or medium‐sized lymphocytes was seen in 18/19 (95%). Granulomatous inflammation was identified in 4/19 (21%). Aberrant loss of CD2, CD5, or CD7 was identified in 1/18 (6%), 2/18 (11%), or 7/19 (37%) cases, respectively. Seventeen of eighteen evaluable cases (95%) expressed 2 to 3 TFH markers: PD‐1 in 19/19 (100%), BCL6 in 94% (17/18), and CD10 in 37% (7/19). EBV‐positive cells were detected in 3/18 (17%) with varying density. Clonal TCR gene rearrangement was identified in 9/11 (82%). Conclusions Cutaneous involvement by AITL shows relatively non‐specific histopathological features. However, an immunohistochemical panel including TFH markers and EBER ISH is useful in differential diagnosis.

show abstract

“…[11][12][13][14][16][17][18][19] The most recent studies showed an incidence of <0.5% of skin infiltration. 15 The marked decrease in the (eg, primary cutaneous follicle center and cutaneous marginal zone lymphoma) [25][26][27] (summarized in Table 3). LyP is characterized by the presence of small papules or nodules, with or without ulceration, that spontaneously heal with scarring, over the course of weeks.…”

Section: Discussionmentioning

confidence: 99%

Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients

et al. 2021

View full text Add to dashboard Cite

Background: Cutaneous involvement by classic Hodgkin lymphoma (CHL) is an extraordinarily rare phenomenon in the current era. To date, no single large case series of cutaneous involvement by Hodgkin lymphoma has ever been reported in the literature.Methods: A comprehensive search for cases designated "skin" and "Hodgkin" was performed at different institutions between 1990 and 2020. Twenty-five cases were identified, and each case was independently reviewed by at least three boardcertified dermatopathologists and/or hematopathologists. Results: All cases represented examples of systemic CHL with secondary skin dissemination. A single lesion, usually a tumor, nodule or infiltrative plaque was observed in 56% of cases and multiple lesions were present in 28% of cases. Most patients (86%-12/14) had a diagnosis of stage IV disease at first diagnosis. The interval between the clinical (first) diagnosis of HL and the development of skin lesions ranged between 6 and 108 months (average 33.75 months). Comprehensive histopathologic evaluation of these cases (at the initial diagnosis) revealed a diagnosis of classic HL not otherwise specified (NOS) in 60% of cases (15/25), nodular sclerosis type in 24% (6/25), mixed cellularity in 12% (3/25), and lymphocyte depleted in 4% (1/25).Conclusions: We provide documentation of a large series of CHL with secondary skin

show abstract

Extranodal Marginal Zone Lymphoma–like Presentations of Angioimmunoblastic T-Cell Lymphoma

Cited by 19 publications

References 65 publications

Cutaneous reactive B‐cell lymphoid proliferations

Cutaneous reactive B‐cell lymphoid proliferations

Cutaneous lesions of angioimmunoblastic T‐cell lymphoma: Clinical, pathological, and immunophenotypic features

Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients

Contact Info

Product

Resources

About